Li Xiao-Lin, Guo Yuan-Lin, Zhu Cheng-Gang, Xu Rui-Xia, Qing Ping, Wu Na-Qiong, Jiang Li-Xin, Xu Bo, Gao Run-Lin, Li Jian-Jun
Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, XiCheng District, Beijing, China (X.L.L., Y.L.G., C.G.Z., R.X.X., P.Q., N.Q.W., L.X.J., B.X., R.L.G., J.J.L.).
J Am Heart Assoc. 2015 Jan 8;4(1):e001412. doi: 10.1161/JAHA.114.001412.
Recent data showed inconsistent association of high-density lipoprotein cholesterol (HDL-C) with cardiovascular risk in patients with different levels of low-density lipoprotein cholesterol (LDL-C) or intensive statin therapy. This study sought to determine the relationship of HDL-C with periprocedural myocardial injury following elective percutaneous coronary intervention (PCI) across a range of LDL-C levels, especially in patients with LDL-C <70 mg/dL.
We enrolled 2529 consecutive patients with normal preprocedural cardiac troponin I (cTnI) who underwent elective PCI. The association between preprocedural HDL-C and periprocedural myocardial injury was evaluated across LDL-C levels, especially in patients with LDL-C <70 mg/dL. The HDL-C level was not predictive of periprocedural myocardial injury across the entire study cohort. However, among patients with LDL-C <70 mg/dL, a 1 mg/dL increase in HDL-C was associated with a 3% reduced risk for postprocedural cTnI above 1×upper limit of normal (ULN) (odds ratio: 0.97; 95% CI: 0.95 to 0.99; P=0.004), a 3% reduced risk for postprocedural cTnI above 3×ULN odds ratio: 0.97; 95% CI: 0.95 to 0.99; P=0.022), and a 3% reduced risk for postprocedural cTnI above 5×ULN (odds ratio: 0.97; 95% CI: 0.95 to 0.99; P=0.017). The relation between plasma HDL-C level and risk of postprocedural cTnI elevation above 1×ULN, 3×ULN, and 5×ULN was modified by LDL-C level (all P for interaction <0.05).
Higher HDL-C levels were associated with reduced risk of periprocedural myocardial injury only in patients with LDL-C <70 mg/dL.
近期数据显示,在低密度脂蛋白胆固醇(LDL-C)水平不同或接受强化他汀类药物治疗的患者中,高密度脂蛋白胆固醇(HDL-C)与心血管风险之间的关联并不一致。本研究旨在确定在一系列LDL-C水平下,尤其是LDL-C<70mg/dL的患者中,HDL-C与择期经皮冠状动脉介入治疗(PCI)后围手术期心肌损伤之间的关系。
我们纳入了2529例术前心肌肌钙蛋白I(cTnI)正常且接受择期PCI的连续患者。在不同LDL-C水平下,尤其是LDL-C<70mg/dL的患者中,评估术前HDL-C与围手术期心肌损伤之间的关联。在整个研究队列中,HDL-C水平并不能预测围手术期心肌损伤。然而,在LDL-C<70mg/dL的患者中,HDL-C每升高1mg/dL,术后cTnI高于正常上限(ULN)1倍的风险降低3%(比值比:0.97;95%可信区间:0.95至0.99;P=0.004),术后cTnI高于3倍ULN的风险降低3%(比值比:0.97;95%可信区间:0.95至0.99;P=0.022),术后cTnI高于5倍ULN的风险降低3%(比值比:0.97;95%可信区间:0.95至0.99;P=0.017)。血浆HDL-C水平与术后cTnI升高超过1倍ULN、3倍ULN和5倍ULN风险之间的关系受到LDL-C水平的影响(所有交互作用P值<0.05)。
仅在LDL-C<70mg/dL的患者中,较高的HDL-C水平与围手术期心肌损伤风险降低相关。